Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccin | DVAX Message Board Posts

Dynavax Technologies Corporation

  DVAX website

DVAX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1702 of 1764  at  6/16/2020 6:20:14 PM  by

fairvalueforyou


 In response to msg 1701 by  liuyiiv
view thread

Re: Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19

NVAX nanoparticle protein subunit platform with Matrix-M was deployed into its pipeline vaccine development just 5 or 6 years ago. Its first nanoparticle protein subunit vaccine with Matrix-M, NanoFlu just successfully completed its phase III trial two months ago. The same platform was used to develop SARS, MERS and Ebola, here is very impressive Ebola phase I trial result as well as NHP challenge trial result
 
CEPI gave 388 millions to NVAX based on its NVX-CoV2373 pre-clinical data, which is largest investment CEPI has done so far.
 
NVX-CoV2373 will be the best in class for covid-19 vaccines when its phase I immunological data becoming available in later July to compare to any other front runner covid-19 phase I data 
 
 
 
 
 
Novavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial on WHO Teleconference

GAITHERSBURG, Md., July 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M™ as part of the World Health Organization’s (WHO) Fifth Teleconference on Ebola Vaccine Clinical Trials. The trial demonstrated that the Ebola GP Vaccine was highly immunogenic, well-tolerated and, in conjunction with Novavax’ proprietary Matrix-M adjuvant, resulted in significant antigen dose-sparing.

The Ebola GP Vaccine clinical trial is a randomized, observer-blinded, dose-escalation trial to evaluate the safety and immunogenicity of the vaccine, with and without Matrix-M, in 230 healthy adults between 18 and 49 years of age. Participants received either one or two intramuscular injections ranging from 6.5µg to 50µg of antigen on study days 0 and 21. Immunogenicity was assessed at multiple time points including days 28 and 35.

The adjuvanted Ebola GP Vaccine was highly immunogenic at all dose levels. The adjuvanted two-dose regimens induced Ebola anti-GP antibody geometric mean responses between 45,000 and 70,000 ELISA units (GMEU), representing a 500 to 750-fold rise over baseline at day 35. The adjuvanted single dose vaccine regimen induced GMEU between 1700 and 3400, representing a 21 to 27-fold rise over baseline at day 35.

 
 
 
 
 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 68
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.


Loading...